NASDAQ:ACRS Aclaris Therapeutics (ACRS) Stock Forecast, Price & News $6.07 -0.19 (-3.04%) (As of 09:58 AM ET) Add Compare Share Share Today's Range$6.03▼$6.2550-Day Range$6.26▼$9.8752-Week Range$5.77▼$18.96Volume59,652 shsAverage Volume830,833 shsMarket Capitalization$429.70 millionP/E RatioN/ADividend YieldN/APrice Target$28.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aclaris Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside375.0% Upside$28.83 Price TargetShort InterestBearish9.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 6 Articles This WeekInsider TradingAcquiring Shares$99,994 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.82) to ($1.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector777th out of 965 stocksPharmaceutical Preparations Industry368th out of 449 stocks 3.5 Analyst's Opinion Consensus RatingAclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.83, Aclaris Therapeutics has a forecasted upside of 375.0% from its current price of $6.07.Amount of Analyst CoverageAclaris Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.21% of the outstanding shares of Aclaris Therapeutics have been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Aclaris Therapeutics has recently increased by 14.39%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRS. Previous Next 3.7 News and Social Media Coverage News SentimentAclaris Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aclaris Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for ACRS on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have bought 127.67% more of their company's stock than they have sold. Specifically, they have bought $99,994.00 in company stock and sold $43,920.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Aclaris Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aclaris Therapeutics are expected to decrease in the coming year, from ($1.82) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aclaris Therapeutics (NASDAQ:ACRS) StockAclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Read More ACRS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRS Stock News HeadlinesOctober 4, 2023 | markets.businessinsider.comBuy Rating Affirmed for Aclaris Therapeutics: Promising Developments in Eczema Treatment Trials and Prospective PartnershipsOctober 3, 2023 | finance.yahoo.comAclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)October 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. October 1, 2023 | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 14.4% in SeptemberSeptember 20, 2023 | finance.yahoo.comWe Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business GrowthSeptember 20, 2023 | finance.yahoo.comAclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceSeptember 19, 2023 | markets.businessinsider.comExpert Ratings for Aclaris TherapeuticsSeptember 19, 2023 | markets.businessinsider.comJefferies Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)October 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.September 18, 2023 | finance.yahoo.comAclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 InhibitorSeptember 14, 2023 | finance.yahoo.comWhy Aclaris Therapeutics Stock Soared Nearly 6% on ThursdaySeptember 11, 2023 | finance.yahoo.comInsider Buying: CFO Kevin Balthaser Acquires 9,490 Shares of Aclaris Therapeutics IncAugust 29, 2023 | seekingalpha.comAclaris Therapeutics rises 13% on insider buyAugust 10, 2023 | finance.yahoo.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Are Cutting Their Estimates: Here's What You Need To KnowAugust 9, 2023 | msn.comHC Wainwright & Co. Reiterates Aclaris Therapeutics (ACRS) Buy RecommendationAugust 8, 2023 | finance.yahoo.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Just Slashed This Year's Revenue Estimates By 11%August 7, 2023 | finanznachrichten.deAclaris Therapeutics, Inc.: Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateAugust 1, 2023 | finance.yahoo.comInvesting in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 363% gainJuly 11, 2023 | seekingalpha.comAclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must WatchJune 26, 2023 | finance.yahoo.com2 Low-Priced Stocks That Could Make You RicherJune 14, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)June 13, 2023 | finance.yahoo.comAclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)June 2, 2023 | finance.yahoo.comAclaris Therapeutics to Participate in Two June Healthcare Investor ConferencesMay 25, 2023 | fool.comAclaris Therapeutics (NASDAQ: ACRS)May 22, 2023 | msn.comAclaris Therapeutics Earnings Perspective: Return On Capital EmployedMay 17, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)May 17, 2023 | msn.comUnusual Call Option Trade in Aclaris Therapeutics (ACRS) Worth $115.50KSee More Headlines Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Company Calendar Last Earnings8/07/2023Today10/04/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRS CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees100Year Founded2012Price Target and Rating Average Stock Price Forecast$28.83 High Stock Price Forecast$43.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+382.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,910,000.00 Net Margins-337.90% Pretax Margin-337.90% Return on Equity-54.43% Return on Assets-42.66% Debt Debt-to-Equity RatioN/A Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual Sales$29.75 million Price / Sales14.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.96 per share Price / Book2.11Miscellaneous Outstanding Shares70,790,000Free Float66,901,000Market Cap$443.15 million OptionableOptionable Beta0.67 Social Links 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Neal S. Walker D.O. (Age 53)Co-Founder & Chairman Comp: $955.69kDr. Douglas J. Manion Frcp(C) (Age 62)M.D., CEO, Pres & Director Comp: $572.16kDr. Joseph Monahan Ph.D. (Age 67)Chief Scientific Officer Comp: $600.02kDr. Gail Cawkwell M.D. (Age 60)Ph.D., Chief Medical Officer Comp: $371.17kMr. Kevin Balthaser (Age 36)Chief Financial Officer Mr. Robert A. Doody Jr.VP of Investor RelationsMr. Matthew Rothman J.D.Gen. Counsel & Corp. Sec.Ms. Jill ConwellChief People OfficerMr. Gary A. DeCrescenzoSr. VP of Pharmaceutical R&DDr. Jon Jacobsen Ph.D.Sr. VP of ChemistryMore ExecutivesKey CompetitorsTheravance BiopharmaNASDAQ:TBPH23andMeNASDAQ:MEBiomea FusionNASDAQ:BMEAJanux TherapeuticsNASDAQ:JANXAvidity BiosciencesNASDAQ:RNAView All CompetitorsInsiders & InstitutionsBarclays PLCSold 103,301 shares on 9/21/2023Ownership: 0.121%James LoeropBought 14,705 shares on 8/28/2023Total: $99,994.00 ($6.80/share)Wolverine Trading LLCSold 1,800 shares on 8/23/2023Ownership: 0.000%Joseph MonahanSold 6,000 sharesTotal: $43,920.00 ($7.32/share)California State Teachers Retirement SystemBought 2,076 shares on 8/21/2023Ownership: 0.095%View All Insider TransactionsView All Institutional Transactions ACRS Stock - Frequently Asked Questions Should I buy or sell Aclaris Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRS shares. View ACRS analyst ratings or view top-rated stocks. What is Aclaris Therapeutics' stock price forecast for 2023? 7 Wall Street research analysts have issued 12-month target prices for Aclaris Therapeutics' shares. Their ACRS share price forecasts range from $20.00 to $43.00. On average, they anticipate the company's stock price to reach $28.83 in the next twelve months. This suggests a possible upside of 360.6% from the stock's current price. View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts. How have ACRS shares performed in 2023? Aclaris Therapeutics' stock was trading at $15.75 at the beginning of 2023. Since then, ACRS shares have decreased by 60.3% and is now trading at $6.26. View the best growth stocks for 2023 here. Are investors shorting Aclaris Therapeutics? Aclaris Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 6,520,000 shares, an increase of 14.4% from the August 31st total of 5,700,000 shares. Based on an average daily trading volume, of 715,100 shares, the days-to-cover ratio is presently 9.1 days. View Aclaris Therapeutics' Short Interest. When is Aclaris Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ACRS earnings forecast. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings data on Monday, August, 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.03. The biotechnology company had revenue of $1.90 million for the quarter, compared to analysts' expectations of $1.90 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 54.43% and a negative net margin of 337.90%. The business's revenue was up 26.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.31) EPS. What ETFs hold Aclaris Therapeutics' stock? ETFs with the largest weight of Aclaris Therapeutics (NASDAQ:ACRS) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What is Neal Walker's approval rating as Aclaris Therapeutics' CEO? 1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX). What is Aclaris Therapeutics' stock symbol? Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS." How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aclaris Therapeutics' stock price today? One share of ACRS stock can currently be purchased for approximately $6.26. How much money does Aclaris Therapeutics make? Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $443.15 million and generates $29.75 million in revenue each year. The biotechnology company earns $-86,910,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. How can I contact Aclaris Therapeutics? Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344. This page (NASDAQ:ACRS) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.